Replies to post #208706 on Elite Pharmaceuticals Inc (ELTP)

[kennyt 335]

The ones you speak of are already lost, GOD willing they find the strength to get off drugs. But the future patients who need pain meds, thats what we are here for. But you know that, right?

[NASDAQ2020]

New users will never experience that first euphoria, which would leave them wanting more.

[Couch]

Or how many would it divert to heroin or fentanyl and kill them?

More like how many teenagers would it divert from becoming addicted in the first place? How much money would it save in ER expenses to begin with? And why did the FDA come out with generic ADT opioid guidelines?

ADT opioids like seat belts are the right thing in the first place. Just like every car has a seat belt the FDA will slowly but surely move towards first removing generic non ADT opioids off the market.

AND we all know that Elite already has the technology to make a generic Embeda and soon ALO-02.

http://www.elitepharma.com/pipeline-generics/

Tell me how many ADTs does Elite have to market before it gets bought out - 1, 2, 3?

THE NEXT RUN is coming and WE ALL KNOW IT = $$$$$$$$$$$$$

Elite Announces U.S. FDA Priority Review Designation For SequestOx™ NDA
SequestOx™ NDA Submission Accepted for Review

NORTHVALE, N.J., March 17, 2016 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCBB:ELTP) today announced that the New Drug Application (NDA) for SequestOXTM (ELI-200), Elite's lead opioid abuse-deterrent candidate for the management of moderate to severe pain where the use of an opioid analgesic is appropriate, has been accepted and granted priority review by the United States Food and Drug Administration ("FDA"). The FDA has set a target action date under the Prescription Drug User Fee Act ("PDUFA") of July 14, 2016.